QNRX

Quoin Pharmaceuticals, Ltd. (QNRX) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.6 (Weak)

Historical revenue CAGR is unavailable and TTM profitability remains negative, so there is no filing-based evidence of durable revenue compounding versus peers.

Minimal capital intensity can support scaling if demand emerges, but current metrics do not show the repeatable growth conversion seen in stronger peers.

Negative ROIC indicates reinvested capital has not yet translated into value-accretive expansion, limiting confidence in long-term revenue compounding relative to peers.

No disclosed segment concentration or customer expansion data is available, so the company lacks peer-level evidence of scalable commercial traction.

Market Tailwinds

Score:

No filing evidence shows a durable end-market tailwind that is converting into sustained revenue growth, unlike peers with proven multi-year demand expansion.

The available metrics do not demonstrate that external demand is large enough or persistent enough to offset the company’s weak operating performance.

Absent segment disclosure and growth history, there is no evidence of a structurally expanding market translating into repeatable revenue gains.

Compared with peers that can point to recurring demand and visible backlog, QNRX currently shows limited proof of market-led growth durability.

Scalability Expansion

Score:

Very low reported capex intensity suggests the model could scale operationally, but peer comparison is constrained because revenue expansion has not been demonstrated.

Negative cash conversion and negative ROIC imply that current operations are not yet scaling into efficient compounding, unlike stronger peers.

Leverage appears modest, which preserves flexibility, but financial capacity alone does not create scalable growth without proven commercial execution.

The absence of disclosed reinvestment metrics such as R&D intensity or segment growth limits evidence that expansion can compound over time.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint because it shows capital deployment has not yet supported durable growth creation versus peers.

Missing five-year growth history and segment data reduce visibility into repeatability, making long-term scaling harder to evidence than for better-disclosed peers.

Negative free cash flow yield and weak operating metrics suggest internal funding for expansion is limited, constraining compounding capacity.

The company’s current profile looks more like early-stage or impaired scaling than durable compounding, especially relative to peers with proven growth engines.

Overall Score

Score:

QNRX shows limited evidence of durable long-term revenue compounding, with negative ROIC and weak operating metrics outweighing any theoretical scalability from low capital intensity.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Quoin Pharmaceuticals, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →